-
1
-
-
39149103122
-
Locally advanced and inflammatory breast cancer
-
Chia S, Swain SM, Byrd DR, et al. Locally advanced and inflammatory breast cancer. J Clin Oncol 2008;26:786-90.
-
(2008)
J Clin Oncol
, vol.26
, pp. 786-790
-
-
Chia, S.1
Swain, S.M.2
Byrd, D.R.3
-
2
-
-
36448985969
-
Preoperative chemotherapy treatment of breast cancer-a review
-
Buzdar AU. Preoperative chemotherapy treatment of breast cancer-a review. Cancer 2007;110:2394-407.
-
(2007)
Cancer
, vol.110
, pp. 2394-2407
-
-
Buzdar, A.U.1
-
3
-
-
0035751675
-
Preoperative chemotherapy in patients with operable breast cancer: Nine-year results from national surgical adjuvant breast and bowel project B-18
-
Wolmark N, Wang J, Mamounas E, et al. Preoperative chemotherapy in patients with operable breast cancer: Nine-year results from national surgical adjuvant breast and bowel project B-18. J Natl Cancer Inst Monogr 2001;30:96-102.
-
(2001)
J Natl Cancer Inst Monogr
, vol.30
, pp. 96-102
-
-
Wolmark, N.1
Wang, J.2
Mamounas, E.3
-
4
-
-
16644384267
-
Randomized parallel study of doxorubicin plus paclitaxel and doxorubicin plus cyclophosphamide as neoadjuvant treatment of patients with breast cancer
-
Dieras V, Fumoleau P, Romieu G, et al. Randomized parallel study of doxorubicin plus paclitaxel and doxorubicin plus cyclophosphamide as neoadjuvant treatment of patients with breast cancer. J Clin Oncol 2004;22:4958-65.
-
(2004)
J Clin Oncol
, vol.22
, pp. 4958-4965
-
-
Dieras, V.1
Fumoleau, P.2
Romieu, G.3
-
5
-
-
33646445341
-
Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National surgical adjuvant breast and bowel project protocol B-27
-
Bear HD, Anderson S, Smith RE, et al. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National surgical adjuvant breast and bowel project protocol B-27. J Clin Oncol 2006;24:2019-27.
-
(2006)
J Clin Oncol
, vol.24
, pp. 2019-2027
-
-
Bear, H.D.1
Anderson, S.2
Smith, R.E.3
-
6
-
-
2642585065
-
A novel continuous infusional 5-fluorouracil-based chemotherapy regimen compared with conventional chemotherapy in the neo-adjuvant treatment of early breast cancer: 5 year results of the TOPIC trial
-
Smith IE, A'Hern R P, Coombes GA, et al. A novel continuous infusional 5-fluorouracil-based chemotherapy regimen compared with conventional chemotherapy in the neo-adjuvant treatment of early breast cancer: 5 year results of the TOPIC trial. Ann Oncol 2004;15:751-8.
-
(2004)
Ann Oncol
, vol.15
, pp. 751-758
-
-
Smith, I.E.1
A'Hern, R.P.2
Coombes, G.A.3
-
7
-
-
34247262143
-
A phase II study of epirubicin, cisplatin and capecitabine as neoadjuvant chemotherapy in locally advanced or inflammatory breast cancer
-
Villman K, Ohd J F, Lidbrink E, et al. A phase II study of epirubicin, cisplatin and capecitabine as neoadjuvant chemotherapy in locally advanced or inflammatory breast cancer. Eur J Cancer 2007;43:1153-60.
-
(2007)
Eur J Cancer
, vol.43
, pp. 1153-1160
-
-
Villman, K.1
Ohd, J.F.2
Lidbrink, E.3
-
8
-
-
12144281589
-
Docetaxel and cisplatin as primary chemotherapy for treatment of locally advanced breast cancers
-
Lee YJ, Doliny P, Gomez-Fernandez C, et al. Docetaxel and cisplatin as primary chemotherapy for treatment of locally advanced breast cancers. Clin Breast Cancer 2004;5:371-6.
-
(2004)
Clin Breast Cancer
, vol.5
, pp. 371-376
-
-
Lee, Y.J.1
Doliny, P.2
Gomez-Fernandez, C.3
-
9
-
-
34447545884
-
Multicenter phase II trial of neoadjuvant therapy with trastuzumab, docetaxel, and carboplatin for human epidermal growth factor receptor-2-overexpressing stage II or III breast cancer: Results of the GETN (A)-1 trial
-
Coudert B P, Largillier R, Arnould L, et al. Multicenter phase II trial of neoadjuvant therapy with trastuzumab, docetaxel, and carboplatin for human epidermal growth factor receptor-2-overexpressing stage II or III breast cancer: Results of the GETN (A)-1 trial. J Clin Oncol 2007;25:2678-84.
-
(2007)
J Clin Oncol
, vol.25
, pp. 2678-2684
-
-
Coudert, B.P.1
Largillier, R.2
Arnould, L.3
-
10
-
-
47549084272
-
Tailored preoperative treatment of locally advanced triple negative (hormone receptor negative and HER2 negative) breast cancer with epirubicin, cisplatin, and infusional fluorouracil followed by weekly paclitaxel
-
Torrisi R, Balduzzi A, Ghisini R, et al. Tailored preoperative treatment of locally advanced triple negative (hormone receptor negative and HER2 negative) breast cancer with epirubicin, cisplatin, and infusional fluorouracil followed by weekly paclitaxel. Cancer Chemother Pharmacol; 2008;62:667-72.
-
(2008)
Cancer Chemother Pharmacol
, vol.62
, pp. 667-672
-
-
Torrisi, R.1
Balduzzi, A.2
Ghisini, R.3
-
11
-
-
54949097426
-
Platinum-based chemotherapy in triple-negative breast cancer
-
Sirohi B, Arnedos M, Popat S, et al. Platinum-based chemotherapy in triple-negative breast cancer. Ann Oncol 2008;19:1847-52.
-
(2008)
Ann Oncol
, vol.19
, pp. 1847-1852
-
-
Sirohi, B.1
Arnedos, M.2
Popat, S.3
-
12
-
-
9244223030
-
Phase I/II trial of biweekly paclitaxel and cisplatin in the treatment of metastatic breast cancer
-
Gelmon KA, O'Reilly SE, Tolcher AW, et al. Phase I/II trial of biweekly paclitaxel and cisplatin in the treatment of metastatic breast cancer. J Clin Oncol 1996;14:1185-91.
-
(1996)
J Clin Oncol
, vol.14
, pp. 1185-1191
-
-
Gelmon, K.A.1
O'Reilly, S.E.2
Tolcher, A.W.3
-
13
-
-
0028877036
-
Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: High antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study
-
Gianni L, Munzone E, Capri G, et al. Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: High antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study. J Clin Oncol 1995;13:2688-99.
-
(1995)
J Clin Oncol
, vol.13
, pp. 2688-2699
-
-
Gianni, L.1
Munzone, E.2
Capri, G.3
-
14
-
-
0033050164
-
Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy
-
Kuerer HM, Newman LA, Smith TL, et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 1999;17:460-9.
-
(1999)
J Clin Oncol
, vol.17
, pp. 460-469
-
-
Kuerer, H.M.1
Newman, L.A.2
Smith, T.L.3
-
15
-
-
0031926839
-
Effect of preoperative chemotherapy on the outcome of women with operable breast cancer
-
Fisher B, Bryant J, Wolmark N, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 1998;16:2672-85.
-
(1998)
J Clin Oncol
, vol.16
, pp. 2672-2685
-
-
Fisher, B.1
Bryant, J.2
Wolmark, N.3
-
16
-
-
33847063053
-
The triple negative paradox: Primary tumor chemosensitivity of breast cancer subtypes
-
Carey LA, Dees EC, Sawyer L, et al. The triple negative paradox: Primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 2007;13:2329-34.
-
(2007)
Clin Cancer Res
, vol.13
, pp. 2329-2334
-
-
Carey, L.A.1
Dees, E.C.2
Sawyer, L.3
-
17
-
-
23844549918
-
Breast cancer molecular subtypes respond differently to preoperative chemotherapy
-
Rouzier R, Perou CM, Symmans W F, et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 2005;11:5678-85.
-
(2005)
Clin Cancer Res
, vol.11
, pp. 5678-5685
-
-
Rouzier, R.1
Perou, C.M.2
Symmans, W.F.3
-
18
-
-
0023006005
-
Isolation and expression of a complementary DNA that confers multidrug resistance
-
Gros P, Ben Neriah YB, Croop JM, et al. Isolation and expression of a complementary DNA that confers multidrug resistance. Nature 1986;323:728-31.
-
(1986)
Nature
, vol.323
, pp. 728-731
-
-
Gros, P.1
Ben Neriah, Y.B.2
Croop, J.M.3
-
20
-
-
0029954845
-
Biology of the multidrug resistance-associated protein, MRP
-
Loe DW, Deeley RG, Cole S P. Biology of the multidrug resistance-associated protein, MRP. Eur J Cancer 1996;32A:945-57.
-
(1996)
Eur J Cancer
, vol.32 A
, pp. 945-957
-
-
Loe, D.W.1
Deeley, R.G.2
Cole, S.P.3
-
21
-
-
0036364467
-
Multidrug resistance in cancer: Role of ATP-dependent transporters
-
Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: Role of ATP-dependent transporters. Nat Rev Cancer 2002;2:48-58.
-
(2002)
Nat Rev Cancer
, vol.2
, pp. 48-58
-
-
Gottesman, M.M.1
Fojo, T.2
Bates, S.E.3
-
22
-
-
0030920342
-
Multidrug resistance in breast cancer: A metaanalysis of MDR1/gp170 expression and its possible functional significance
-
Trock BJ, Leonessa F, Clarke R. Multidrug resistance in breast cancer: A metaanalysis of MDR1/gp170 expression and its possible functional significance. J Natl Cancer Inst 1997;89:917-31.
-
(1997)
J Natl Cancer Inst
, vol.89
, pp. 917-931
-
-
Trock, B.J.1
Leonessa, F.2
Clarke, R.3
-
23
-
-
0034667390
-
Extensive contribution of the multidrug transporters P-glycoprotein and Mrp1 to basal drug resistance
-
Allen JD, Brinkhuis R F, van Deemter L, et al. Extensive contribution of the multidrug transporters P-glycoprotein and Mrp1 to basal drug resistance. Cancer Res 2000;60:5761-6.
-
(2000)
Cancer Res
, vol.60
, pp. 5761-5766
-
-
Allen, J.D.1
Brinkhuis, R.F.2
van Deemter, L.3
-
24
-
-
0036569471
-
Assessment of molecular markers of clinical sensitivity to single-agent taxane therapy for metastatic breast cancer
-
Van Poznak C, Tan L, Panageas KS, et al. Assessment of molecular markers of clinical sensitivity to single-agent taxane therapy for metastatic breast cancer. J Clin Oncol 2002;20:2319-26.
-
(2002)
J Clin Oncol
, vol.20
, pp. 2319-2326
-
-
Van Poznak, C.1
Tan, L.2
Panageas, K.S.3
-
25
-
-
4544357777
-
Investigation of MRP-1 protein and MDR-1 P-glycoprotein expression in invasive breast cancer: A prognostic study
-
Larkin A, O'Driscoll L, Kennedy S, et al. Investigation of MRP-1 protein and MDR-1 P-glycoprotein expression in invasive breast cancer: A prognostic study. Int J Cancer 2004;112:286-94.
-
(2004)
Int J Cancer
, vol.112
, pp. 286-294
-
-
Larkin, A.1
O'Driscoll, L.2
Kennedy, S.3
-
26
-
-
33344456074
-
Prognostic impact of multidrug resistance gene expression on the management of breast cancer in the context of adjuvant therapy based on a series of 171 patients
-
Moureau-Zabotto L, Ricci S, Lefranc J P, et al. Prognostic impact of multidrug resistance gene expression on the management of breast cancer in the context of adjuvant therapy based on a series of 171 patients. Br J Cancer 2006;94:473-80.
-
(2006)
Br J Cancer
, vol.94
, pp. 473-480
-
-
Moureau-Zabotto, L.1
Ricci, S.2
Lefranc, J.P.3
-
27
-
-
0026630604
-
P53 mutations in breast cancer
-
Coles C, Condie A, Chetty U, et al. P53 mutations in breast cancer. Cancer Res 1992;52:5291-8.
-
(1992)
Cancer Res
, vol.52
, pp. 5291-5298
-
-
Coles, C.1
Condie, A.2
Chetty, U.3
-
28
-
-
0030865104
-
Characterization of the p53 tumor suppressor pathway in cell lines of the national cancer institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents
-
O'Connor PM, Jackman J, Bae I, et al. Characterization of the p53 tumor suppressor pathway in cell lines of the national cancer institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res 1997;57:4285-300.
-
(1997)
Cancer Res
, vol.57
, pp. 4285-4300
-
-
O'Connor, P.M.1
Jackman, J.2
Bae, I.3
-
29
-
-
17744403009
-
Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer
-
Berns EM, Foekens JA, Vossen R, et al. Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer. Cancer Res 2000;60:2155-62.
-
(2000)
Cancer Res
, vol.60
, pp. 2155-2162
-
-
Berns, E.M.1
Foekens, J.A.2
Vossen, R.3
-
30
-
-
12244252332
-
Predictive value of tumour cell proliferation in locally advanced breast cancer treated with neoadjuvant chemotherapy
-
Aas T, Geisler S, Eide GE, et al. Predictive value of tumour cell proliferation in locally advanced breast cancer treated with neoadjuvant chemotherapy. Eur J Cancer 2003;39:438-46.
-
(2003)
Eur J Cancer
, vol.39
, pp. 438-446
-
-
Aas, T.1
Geisler, S.2
Eide, G.E.3
-
31
-
-
0035866772
-
Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer
-
Geisler S, Lonning PE, Aas T, et al. Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer. Cancer Res 2001;61:2505-12.
-
(2001)
Cancer Res
, vol.61
, pp. 2505-2512
-
-
Geisler, S.1
Lonning, P.E.2
Aas, T.3
-
32
-
-
0141614011
-
Topoisomerase II alpha as a marker predicting the efficacy of anthracyclines in breast cancer: Are we at the end of the beginning?
-
Di Leo A, Isola J. Topoisomerase II alpha as a marker predicting the efficacy of anthracyclines in breast cancer: Are we at the end of the beginning? Clin Breast Cancer 2003;4:179-86.
-
(2003)
Clin Breast Cancer
, vol.4
, pp. 179-186
-
-
Di Leo, A.1
Isola, J.2
-
33
-
-
45149122291
-
The value of TOP2A gene copy number variation as a biomarker in breast cancer: Update of DBCG trial 89D
-
Nielsen KV, Ejlertsen B, Moller S, et al. The value of TOP2A gene copy number variation as a biomarker in breast cancer: Update of DBCG trial 89D. Acta Oncol 2008;47:725-34.
-
(2008)
Acta Oncol
, vol.47
, pp. 725-734
-
-
Nielsen, K.V.1
Ejlertsen, B.2
Moller, S.3
-
34
-
-
84898697559
-
-
NCIC. National cancer institute of canada: Common toxicity criteria (CTC). 2nd ed. NCIC CTG pocket book; 1998.
-
NCIC. National cancer institute of canada: Common toxicity criteria (CTC). 2nd ed. NCIC CTG pocket book; 1998.
-
-
-
-
35
-
-
0019365237
-
Reporting results of cancer treatment
-
Miller AB, Hoogstraten B, Staquet M, et al. Reporting results of cancer treatment. Cancer 1981;47:207-14.
-
(1981)
Cancer
, vol.47
, pp. 207-214
-
-
Miller, A.B.1
Hoogstraten, B.2
Staquet, M.3
-
36
-
-
7044272570
-
Long-term follow-up for locally advanced and inflammatory breast cancer patients treated with multimodality therapy
-
Low JA, Berman AW, Steinberg SM, et al. Long-term follow-up for locally advanced and inflammatory breast cancer patients treated with multimodality therapy. J Clin Oncol 2004;22:4067-74.
-
(2004)
J Clin Oncol
, vol.22
, pp. 4067-4074
-
-
Low, J.A.1
Berman, A.W.2
Steinberg, S.M.3
-
37
-
-
17444454498
-
Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: Findings from national surgical adjuvant breast and bowel project B-18
-
Fisher B, Brown A, Mamounas E, et al. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: Findings from national surgical adjuvant breast and bowel project B-18. J Clin Oncol 1997;15:2483-93.
-
(1997)
J Clin Oncol
, vol.15
, pp. 2483-2493
-
-
Fisher, B.1
Brown, A.2
Mamounas, E.3
-
38
-
-
0037365648
-
Final results of a randomized phase III trial comparing cyclophosphamide, epirubicin, and fluorouracil with a dose-intensified epirubicin and cyclophosphamide + filgrastim as neoadjuvant treatment in locally advanced breast cancer: An EORTC-NCIC-SAKK multicenter study
-
Therasse P, Mauriac L, Welnicka-Jaskiewicz M, et al. Final results of a randomized phase III trial comparing cyclophosphamide, epirubicin, and fluorouracil with a dose-intensified epirubicin and cyclophosphamide + filgrastim as neoadjuvant treatment in locally advanced breast cancer: An EORTC-NCIC-SAKK multicenter study. J Clin Oncol 2003;21:843-50.
-
(2003)
J Clin Oncol
, vol.21
, pp. 843-850
-
-
Therasse, P.1
Mauriac, L.2
Welnicka-Jaskiewicz, M.3
-
39
-
-
58049208408
-
Assessment of different criteria for the pathological complete response (pCR) to primary chemotherapy in breast cancer: Standardization is needed
-
Mukai H, Watanabe T, Ando M, et al. Assessment of different criteria for the pathological complete response (pCR) to primary chemotherapy in breast cancer: Standardization is needed. Breast Cancer Res Treat 2009;113:123-8.
-
(2009)
Breast Cancer Res Treat
, vol.113
, pp. 123-128
-
-
Mukai, H.1
Watanabe, T.2
Ando, M.3
-
40
-
-
39149111633
-
Preoperative chemotherapy: Updates of national surgical adjuvant breast and bowel project protocols B-18 and B-27
-
Rastogi P, Anderson SJ, Bear HD, et al. Preoperative chemotherapy: Updates of national surgical adjuvant breast and bowel project protocols B-18 and B-27. J Clin Oncol 2008;26:778-85.
-
(2008)
J Clin Oncol
, vol.26
, pp. 778-785
-
-
Rastogi, P.1
Anderson, S.J.2
Bear, H.D.3
-
41
-
-
0030805625
-
NSABP protocol B-27. preoperative doxorubicin plus cyclophosphamide followed by preoperative or postoperative docetaxel
-
Mamounas E P. NSABP protocol B-27. preoperative doxorubicin plus cyclophosphamide followed by preoperative or postoperative docetaxel. Oncology Williston Park 1997;11(suppl 6):37-40.
-
(1997)
Oncology Williston Park
, vol.11
, Issue.SUPPL. 6
, pp. 37-40
-
-
Mamounas, E.P.1
-
42
-
-
33846297680
-
Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: An update of the initial randomized study population and data of additional patients treated with the same regimen
-
Buzdar AU, Valero V, Ibrahim NK, et al. Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: An update of the initial randomized study population and data of additional patients treated with the same regimen. Clin Cancer Res 2007;13:228-33.
-
(2007)
Clin Cancer Res
, vol.13
, pp. 228-233
-
-
Buzdar, A.U.1
Valero, V.2
Ibrahim, N.K.3
-
43
-
-
70249123201
-
Neoadjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer: Primary efficacy analysis of the NOAH trial
-
Presented at: December 10-14, San Antonio, TX. Abstract 31
-
Gianni L, Eiermann W, Semiglazov, et al. Neoadjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer: primary efficacy analysis of the NOAH trial. Presented at: the 31st Annual San Antonio Breast Cancer Symposiun; December 10-14, 2008; San Antonio, TX. Abstract 31.
-
(2008)
the 31st Annual San Antonio Breast Cancer Symposiun
-
-
Gianni, L.1
Eiermann, W.2
Semiglazov3
-
44
-
-
38349084668
-
Does estrogen receptor negative/progesterone receptor positive breast carcinoma exist?
-
author reply 336-8
-
De Maeyer L, Van Limbergen E, De Nys K, et al. Does estrogen receptor negative/progesterone receptor positive breast carcinoma exist? J Clin Oncol 2008;26:335; author reply 336-8.
-
(2008)
J Clin Oncol
, vol.26
, pp. 335
-
-
De Maeyer, L.1
Van Limbergen, E.2
De Nys, K.3
-
45
-
-
25144504517
-
Expression of mucins (MUC1, MUC2, MUC3, MUC4, MUC5AC and MUC6) and their prognostic significance in human breast cancer
-
Rakha EA, Boyce RW, Abd El-Rehim D, et al. Expression of mucins (MUC1, MUC2, MUC3, MUC4, MUC5AC and MUC6) and their prognostic significance in human breast cancer. Mod Pathol 2005;18:1295-304.
-
(2005)
Mod Pathol
, vol.18
, pp. 1295-1304
-
-
Rakha, E.A.1
Boyce, R.W.2
Abd El-Rehim, D.3
-
46
-
-
58149359842
-
Triple negative breast cancer: Risk factors to potential targets
-
Schneider B P, Weiner E P, Foulkes WD, et al. Triple negative breast cancer: Risk factors to potential targets. Clin Cancer Res 2008;14:8010-8
-
(2008)
Clin Cancer Res
, vol.14
, pp. 8010-8018
-
-
Schneider, B.P.1
Weiner, E.P.2
Foulkes, W.D.3
|